AFT PHARMACEUTICALS LIMITED (AFP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AFP - AFT PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: March

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: 1.24

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$2.40 08 Oct 2025	0.000 OPEN $2.40	0.000 HIGH $2.40	0 LOW $2.40

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 19/06 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2020	2021	2022	2023	2024	2025
EPS Basic	xxx	xxx	xxx	xxx	xxx	10.4
DPS All	xxx	xxx	xxx	xxx	xxx	1.6
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	189.4 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	84.6
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	9.7 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	5.75 %

EPS Basic

Negative
Growth
Slowing

DPS All

Negative
Growth
Slowing

Sales/Revenue

Negative
Growth
Slowing

Book Value Per Share

Negative
Growth
Slowing

Net Operating Cash Flow

Negative
Growth
Slowing

Net Profit Margin

Negative
Growth
Slowing

Title	2020	2021	2022	2023	2024	2025
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	12.87 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	9.74 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	7.12 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	12.87 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	13.64 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	7.9 M

Return on Capital Employed

Negative
Growth
Slowing

Return on Invested Capital

Negative
Growth
Slowing

Return on Assets

Negative
Growth
Slowing

Return on Equity

Negative
Growth
Slowing

Return on Total Capital

Negative
Growth
Slowing

Free Cash Flow ex dividends

Negative
Growth
Slowing

Title	2020	2021	2022	2023	2024	2025
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	2 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	26 M
Total Debt	xxx	xxx	xxx	xxx	xxx	27 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	10 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	2.89

Short-Term Debt

Negative
Growth
Slowing

Long Term Debt

Negative
Growth
Slowing

Total Debt

Negative
Growth
Slowing

Goodwill - Gross

Cash & Equivalents - Generic

Negative
Growth
Slowing

Price To Book Value

Negative
Growth
Slowing

Title	2020	2021	2022	2023	2024	2025
Capex	xxx	xxx	xxx	xxx	xxx	6.3 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	3.34 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	106 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	68 M
Research & Development	xxx	xxx	xxx	xxx	xxx	10 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Negative
Growth
Slowing

Capex % of Sales

Negative
Growth
Slowing

Cost of Goods Sold

Negative
Growth
Slowing

Selling, General & Admin. Exp & Other

Negative
Growth
Slowing

Research & Development

Negative
Growth
Slowing

Investments - Total

Negative
Growth
Slowing

Negative

Growth

Slowing

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
No data available in table

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Jarden	06/08/2025	2	Overweight	-	-	Jarden maintains an Overweight rating and NZ$3.10 target price following AFT Pharmaceuticals' AGM. Management reaffirmed FY26 revenue guidance and operating profit of NZ$20–24m (Jarden NZ$24.4m). The broker sees the reiterated FY27 revenue target of NZ$300m as credible. A key update, suggests the broker, was the broadened R&D pipeline, which now extends significantly beyond the Maxigesic franchise. Jarden views this expansion as essential to supporting growth past FY27.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Jarden

06/08/2025

Overweight

Jarden maintains an Overweight rating and NZ$3.10 target price following AFT Pharmaceuticals' AGM.

Management reaffirmed FY26 revenue guidance and operating profit of NZ$20–24m (Jarden NZ$24.4m).

The broker sees the reiterated FY27 revenue target of NZ$300m as credible.

A key update, suggests the broker, was the broadened R&D pipeline, which now extends significantly beyond the Maxigesic franchise. Jarden views this expansion as essential to supporting growth past FY27.

Access Extra Coverage Research History >

AFP STOCK CHART

FNArena News on AFP

1	Australian Broker Call Extra Edition – Aug 06, 2025 Aug 06 2025 - Daily Market Reports

2	Next Week At A Glance – 24-28 Jun 2024 Jun 21 2024 - Weekly Reports

3	Next Week At A Glance – 17-21 – Jun 2024 Jun 14 2024 - Weekly Reports

4	In Case You Missed It – BC Extra Upgrades & Downgrades – 07-06-24 Jun 07 2024 - Weekly Reports

5	Australian Broker Call Extra Edition – Jun 03, 2024 Jun 03 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1	Is CSL Starting Its Price Recovery? Sep 30 2025 - Technicals

2	Undervalued ASX Gems In Precision Medicine Sep 23 2025 - Small Caps

3	Earnings Result Leaves CSL Bloodied Aug 21 2025 - Australia

4	Renewed Momentum For CSL Shares Jul 22 2025 - Technicals

5	Treasure Chest: CSL Not A One-Trick Pony Jul 14 2025 - Treasure Chest

6	The Enigma Surrounding Clinuvel Jul 03 2025 - Small Caps

7	Rudi’s View: CSL & NextDC May 08 2025 - Rudi's View

8	Behring Margin Outlook Still Main Game For CSL Feb 13 2025 - Australia

9	Dr Boreham’s Crucible: Arovella Therapeutics Aug 29 2024 - Small Caps

10	ResMed’s Margin Upside Excites Aug 07 2024 - Australia

Get 2 Weeks free trial

Sign Up

Member Login

AFT PHARMACEUTICALS LIMITED (AFP)
Share Price Analysis and Chart